Lates News

date
09/05/2025
Regulus Therapeutics (RGLS.US): Revenue in the first quarter of 2025 was $0, unchanged from the previous quarter; earnings per share were -$0.15, an improvement from -$0.29, with an expected value of -$0.23.
Latest
See all latestmore